Pfizer Inc. (NYSE:PFE) Shares Purchased by IHT Wealth Management LLC

IHT Wealth Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 29.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 179,739 shares of the biopharmaceutical company’s stock after purchasing an additional 41,302 shares during the quarter. IHT Wealth Management LLC’s holdings in Pfizer were worth $5,196,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at $29,000. Gladius Capital Management LP lifted its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP purchased a new position in Pfizer during the 2nd quarter valued at about $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer during the 2nd quarter valued at $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the 3rd quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Down 1.0 %

Shares of NYSE PFE opened at $25.56 on Wednesday. The business has a fifty day moving average of $27.68 and a two-hundred day moving average of $28.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a market cap of $144.85 billion, a PE ratio of 34.54, a PEG ratio of 0.70 and a beta of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.57%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.